Entropy Neurodynamics: Pioneering Precision Psilocin Therapy in the Psychedelic Boom
The medical psychedelic industry is rapidly emerging as a compelling frontier in mental health and neurological therapeutics. Within this burgeoning sector, Sydney-based firm Prenzler Group has initiated coverage on clinical-stage company Entropy Neurodynamics, highlighting its unique approach to psilocin-focused treatments. Prenzler Group identifies Entropy as one of the select few companies targeting somatic (bodily) and pain-related disorders with psychedelics, granting it a significant “first-mover advantage in these large indications.”
Prenzler Group’s analysis underscores a key differentiator for Entropy: its patented precision intravenous (IV) dosing of psilocin. This method is presented as a significant advancement over the oral psilocybin commonly used by many of its peers, promising greater control and potentially superior therapeutic outcomes.
The Precision of IV Psilocin Delivery
Entropy Neurodynamics’ flagship candidate, TRP-8803, is engineered to circumvent the inherent limitations associated with oral psychedelic administration. By enabling precise intravenous delivery of psilocin, TRP-8803 aims to ensure a consistent and predictable onset, depth, and duration of the treatment effect. This controlled delivery is crucial for optimising therapeutic efficacy and patient experience.
The company is strategically positioning TRP-8803 for Phase II trials across a range of indications. This move is supported by encouraging signals observed from earlier studies involving its oral psilocybin candidate, TRP-8802. Notably:
- Binge Eating Disorder (BED): In a Phase IIa trial, TRP-8802 demonstrated a remarkable reduction of over 80% in binge eating episodes.
- Fibromyalgia: An initial study of TRP-8802 in fibromyalgia patients reported that 100% experienced pain relief and an improved quality of life.
- Irritable Bowel Syndrome (IBS): Interim results from a Phase IIa trial evaluating TRP-8802 for IBS also yielded positive outcomes.
While TRP-8802 has been instrumental in generating these early efficacy signals, Prenzler Group acknowledges its role as a valuable precursor. “Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 with the potential to deliver improved efficacy, safety, and a more controlled patient experience,” the report states.
Overcoming the Hurdles of Oral Psilocin
The promise of psilocybin, the psychoactive compound found in magic mushrooms, is well-documented in early research. However, Prenzler Group points out that oral delivery presents substantial practical and clinical challenges. These include:
- Unpredictable Onset and Duration: Patients can take anywhere from one to four hours to reach peak effect, with entire sessions potentially lasting up to eight hours, necessitating extended supervision.
- Variable Dosing Precision: Liver metabolism can significantly impact the consistency of dosing, leading to situations where up to 30% of patients may not achieve optimal therapeutic levels, while others might experience adverse effects like nausea or paranoia.
- Irreversibility of Effects: Once administered, the psychedelic effects of oral dosing cannot be reversed, posing constraints on safety, logistics, and scalability for widespread clinical application.
Entropy’s IV psilocin therapy is specifically designed to address these obstacles, offering several key advantages:
- Reduced Session Times: Treatment sessions are significantly shorter, typically lasting around two hours. This reduction in duration eases the burden on patients, lowers supervisory costs for clinics, and improves overall clinic throughput.
- Rapid and Predictable Onset: The psychedelic state is achieved rapidly, generally within 15 minutes, allowing clinicians to initiate treatment promptly and manage session timing more effectively.
- Precise Blood Level Control: IV administration permits precise targeting and maintenance of psilocin blood levels. Clinicians can adjust dosing in real time, keeping patients within the desired therapeutic zone. This minimises variability in treatment response and reduces the risk of under- or over-exposure.
Developing Novel Brain Biomarkers for Precision Psychiatry
Entropy Neurodynamics is also at the forefront of developing objective measures for psychedelic therapy. The company has forged a partnership with renowned psychedelic neuroscience researchers, Professor Robin Carhart-Harris and Professor Pedro Mediano. Together, they are working to create a novel electroencephalogram (EEG) based brain biomarker for TRP-8803.
This innovative biomarker aims to provide real-time insights into brain activity during TRP-8803 administration. Utilising machine-learning algorithms and closed-loop EEG monitoring, the program seeks to define the optimal neuroplasticity window during infusion. Prenzler Group highlights the significance of this initiative: “This program aims to create the first regulatory-grade physiological biomarker for psychedelic therapy, offering objective measures of treatment effect, improved patient selection capabilities, and enhanced safety through real-time dose modulation.”
A Robust Intellectual Property Portfolio
A cornerstone of Entropy’s long-term commercial strategy is its extensive intellectual property (IP) portfolio. This is anchored by a granted Australian patent that safeguards its precision-controlled IV delivery method for TRP-8803. This patent, which extends to 2042, covers a proprietary two-phase dosing model:
- Rapid Loading Dose: Designed to induce a therapeutic state within five to 30 minutes.
- Controlled Maintenance Infusion: To stabilise plasma levels and sustain the therapeutic effect.
Furthermore, the patent encompasses the use of EEG-based monitoring to support biomarker development and precision psychiatry applications. The patent’s claims extend to psilocybin, psilocin, and related chemical variants, covering a broad spectrum of high-value indications, including anxiety, post-traumatic stress disorder (PTSD), addiction, eating disorders, fibromyalgia, and nociplastic pain. Corresponding patent applications are currently under review in several other jurisdictions, and Entropy has also filed provisional applications for the use of psilocybin and its derivatives in conditions such as BED, fibromyalgia, and IBS.
Navigating the Expanding Psychedelic Market
Entropy Neurodynamics operates within a rapidly growing global market for psychedelic therapies. This sector is characterised by well-capitalised, Nasdaq-listed companies advancing late-stage clinical programs. The increasing global burden of mental health issues and a paradigm shift towards novel treatment modalities are driving significant investment and innovation.
Market projections indicate robust growth for the psychedelic drugs market, with an estimated value of around US$3.9 billion in 2025. This figure is anticipated to more than double to approximately US$9.6 billion by 2032, representing a compound annual growth rate of circa 14%.
Financial Strength and Upcoming Milestones
Following a significant $6.1 million institutional placement in November and a $2.6 million R&D credit advance, Entropy Neurodynamics is well-positioned to achieve its near-term strategic objectives. Key upcoming milestones include:
- Current Quarter: Final data from the Phase IIa TRP-8802 IBS trial.
- End of March: Topline results from the BED trial, contingent on ongoing recruitment and dosing.
- June: Final data from the BED trial.
- This Quarter: Launch of a new major TRP-8803 clinical trial.
